Developing a Patient-Reported Outcome Measure for Radionuclide Therapy for Prostate Cancer.

Authors

• Lisa M Gudenkauf
• Melody N Chavez
• Melinda Leigh Maconi
• Carley Geiss
• Ameen Seyedroudbari
• Pan Thin
• Aasha I Hoogland
• Kathleen Nguyen
• Vishnu Murthy
• Wesley R Armstrong
• Khaled Komrokji
• Laura B Oswald
• Heather S L Jim
• Ghassan El-Haddad
• Wolfgang P Fendler
• Ken Herrmann
• David Cella
• Johannes Czernin
• Michael S Hofman
• Adam P Dicker
• Jeremie Calais
• Scott T Tagawa
• Brian D Gonzalez

Publication/Presentation Date

6-1-2023

Abstract

The field of radionuclide therapy (RNT) for prostate cancer (PC) is growing rapidly, with recent Food and Drug Administration approval of the first

Volume

64

Issue

6

First Page

869

Last Page

872

ISSN

1535-5667

Published In/Presented At

Gudenkauf, L. M., Chavez, M. N., Maconi, M. L., Geiss, C., Seyedroudbari, A., Thin, P., Hoogland, A. I., Nguyen, K., Murthy, V., Armstrong, W. R., Komrokji, K., Oswald, L. B., Jim, H. S. L., El-Haddad, G., Fendler, W. P., Herrmann, K., Cella, D., Czernin, J., Hofman, M. S., Dicker, A. P., … Gonzalez, B. D. (2023). Developing a Patient-Reported Outcome Measure for Radionuclide Therapy for Prostate Cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 64(6), 869–872. https://doi.org/10.2967/jnumed.122.264946

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

PubMedID

36635088

Department(s)

Administration and Leadership

Document Type

Article